Diagnostic problems of rare diseases - amyloidosis. A case report
DOI:
https://doi.org/10.12775/JEHS.2024.56.003Keywords
cardiac amyloidosis, amyloid, heart failure, brain failure, amyloidosis AL, amyloidosis treatmentAbstract
The presented case study focuses on the complexities and challenges in diagnosing
one of the forms of amyloidosis, where abnormal protein (amyloid) deposits in various
organs and tissues lead to affection of many organs, especially the heart, kidneys, liver,spleen, and occasionally the central nervous system. Its aetiology remains largely unknown,
making diagnosis and treatment particularly challenging.
This report details the case of an 88-year-old patient, disabled for months (with a
modified Rankin Scale score of 4), who presented to the Neurology Department with sudden
right limb paresis and speech disorders. Initial assessments indicated suggested ischemic
stroke, and patients received thrombolysis. Further laboratory tests and imaging, including
serum protein electrophoresis and computer tomograph (CT) scans, suggested transthyretin
amyloidosis (ATTR), which was later confirmed through genetic testing.
This case underscores the rapid, multi-organ progression of amyloidosis and its
devastating impact, highlighting the necessity for early diagnosis and a multidisciplinary
treatment approach.
Despite ongoing research, the pathogenesis of amyloidosis remains elusive, and
current treatment options are primarily symptomatic. This study aims to shed light on the
diagnostic difficulties and the urgent need for timely intervention in amyloidosis cases.
References
Ruberg, F. L., & Berk, J. L. (2012). Transthyretin (TTR) cardiac amyloidosis. Circulation,
(10), 1286–1300. https://doi.org/10.1161/CIRCULATIONAHA.111.078915/-/DC1
Pawłowski, Z. Amyloidoza transtyretynowa – niebezpieczna choroba rzadka atakująca serce -
Polska Sieć Amyloidozy. (n.d.). Retrieved January 2, 2024, from
https://amyloidoza.edu.pl/aktualnosci/amyloidoza-transtyretynowa-niebezpieczna-choroba-
rzadka-atakujaca-serce/
Filipowicz-Sosnowska, A., Goncerz, G. Podręcznik Interna - Medycyna Praktyczna:
Amyloidoza. (n.d.). Retrieved January 2, 2024, from
https://www.mp.pl/interna/chapter/B16.II.16.24.
Wiercińska, M. Amyloidoza (skrobawica) | Reumatologia - mp.pl. (n.d.). Retrieved January 2,
, from https://www.mp.pl/pacjent/reumatologia/choroby/143459,amyloidoza-skrobawica
Obi, Chukwuemeka A, William C Mostertz, Jan M Griffin, and Daniel P Judge. 2022. “ATTR
Epidemiology, Genetics, and Prognostic Factors.” Methodist DeBakey Cardiovascular Journal
(2): 17–26. https://doi.org/10.14797/mdcvj.1066.
Roger, Véronique L. 2021. “Epidemiology of Heart Failure: A Contemporary Perspective.”
Circulation Research 128 (10): 1421–34. https://doi.org/10.1161/CIRCRESAHA.121.318172.
Tsoi, M.R., Lin, J.H. & Patel, A.R. Emerging Therapies for Transthyretin Amyloidosis. Curr
Oncol Rep 25, 549–558 (2023). https://doi.org/10.1007/s11912-023-01397-2
Benson, M. D. (n.d.). (2001). Amyloidosis. Nature Publishing Group. Retrieved January 2,
, from www.els.net
Holcman, K., Kostkiewicz, M., Podolec, P., Rubiś, P. (2020). Amyloidoza serca — właściwe
rozpoznanie i nowe terapie na horyzoncie. Varia Medica, 4(1), 29–37.
https://doi.org/10.5603/FC.2019.0115
Pawłowski, Z. Amyloidoza transtyretynowa - perspektywa pacjenta - Polska Sieć Amyloidozy.
(n.d.). Retrieved January 2, 2024, from https://amyloidoza.edu.pl/aktualnosci/amyloidoza-
transtyretynowa-perspektywa-pacjenta/
Merlini, G., Seldin, D. C., & Gertz, M. A. (2011). Amyloidosis: Pathogenesis and New
Therapeutic Options. Journal of Clinical Oncology, 29(14), 1924.
https://doi.org/10.1200/JCO.2010.32.2271
Sperry, Brett W, Bryan A Reyes, Asad Ikram, Joseph P Donnelly, Dermot Phelan, Wael A
Jaber, David Shapiro, et al. 2018. “Tenosynovial and Cardiac Amyloidosis in Patients
Undergoing Carpal Tunnel Release.” Journal of the American College of Cardiology 72 (17):
–50. https://doi.org/10.1016/j.jacc.2018.07.092.
Mohammed, Selma F, Sultan A Mirzoyev, William D Edwards, Ahmet Dogan, Donna R
Grogan, Shannon M Dunlay, Veronique L Roger, et al. 2014. “Left Ventricular Amyloid
Deposition in Patients with Heart Failure and Preserved Ejection Fraction.” JACC. Heart
Failure 2 (2): 113–22. https://doi.org/10.1016/j.jchf.2013.11.004.
Desport, E., Bridoux, F., Sirac, C., Delbes, S., Bender, S., Fernandez, B., Quellard, N.,
Lacombe, C., Goujon, J. M., Lavergne, D., Abraham, J., Touchard, G., Fermand, J. P., &
Jaccard, A. (2012). AL Amyloidosis. Orphanet Journal of Rare Diseases, 7(1), 1–13.
https://doi.org/10.1186/1750-1172-7-54/TABLES/5
Grzybowski, J., Podolec, P., Holcman, K., Gawor-Prokopczyk, M., Jankowska, E.,
Kostkiewicz, M., Dąbrowska-Kugacka, A., Lipowska, M., Mazurkiewicz, Ł., Rajtar-Salwa, R.,
Rubiś, P., Straburzyńska-Migaj, E., Szczygieł, J., Mitkowski, P., Gąsior, Z., Leszek, P. (2023).
Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of
the Polish Cardiac Society. Polish Heart Journal (Kardiologia Polska), 81(11), 1167–1185.
https://doi.org/10.33963/V.KP.97648
Grzybowski, J. ATTR – perspektywa kliniczna – Polska Sieć Amyloidozy. (n.d.). Retrieved
January 2, 2024, from https://amyloidoza.edu.pl/aktualnosci/amyloidoza-transtyretynowa-
serca-perspektywa-kliniczna/
Żelichowski, G., Lubas, A., & Wańkowicz, Z. (n.d.). Postępy diagnostyki i leczenia AL
amyloidozy.
Łyczkowska-Piotrowska, J., Salomon-Perzyński, A., K., Końska, A., Jamroziak, K. (2018).
PRACA POGLĄDOWA Doksycyklina w terapii amyloidozy układowej z zajęciem serca.
Doxycycline in the treatment of systemic amyloidosis with cardiac involvement. (2018).
Hematologia. 9(3), 202-207. DOI:10.5603/Hem.2018.0031
https://doi.org/10.5603/Hem.2018.0027
Milani, P., Merlini, G., & Palladini, G. (2018). Light Chain Amyloidosis. Mediterranean
Journal of Hematology and Infectious Diseases, 10(1).
https://doi.org/10.4084/MJHID.2018.022
Salomon-Perzyński A, Końska A, Puła B. Łyczkowska-Piotrowska, J., Jamroziak, K. Jak
leczymy pacjenta z nowo rozpoznaną amyloidozą łańcuchów lekkich pośredniego ryzyka?
Rola doksycykliny w terapii amyloidozy z zajęciem serca. (2018). Hematologia. 9(3),
–253, DOI: 10.5603/ Hem.2018.0031.
Diomede, L., Rognoni, P., Lavatelli, F., Romeo, M., Del Favero, E., Cantù, L., Ghibaudi, E.,
Di Fonzo, A., Corbelli, A., Fiordaliso, F., Palladini, G., Valentini, V., Perfetti, V., Salmona,
M., & Merlini, G. (2014). A Caenorhabditis elegans-based assay recognizes immunoglobulin
light chains causing heart amyloidosis. Blood, 123(23), 3543–3552.
https://doi.org/10.1182/BLOOD-2013-10-525634
Analiza dowodów naukowych potwierdzających zasadność stosowania wybranych skal do
oceny pacjenta w ramach świadczeń z zakresu rehabilitacji neurologicznej. Agencja Oceny
Technologii Medycznych i Taryfikacji. Wydział Świadczeń Opieki Zdrowotnej. 2019;431(5):53.
Baska, A., Kazik, J., Bojczuk, D., Racinowski, M., Leis, K., Mazur, E., Kałużny, K., &
Gałązka, P. (2019). The journal has had 7 points in Ministry of Science and Higher Education
parametric evaluation. Journal of Education, 9(3), 2391–8306.
http://dx.doi.org/zenodo.2597569
Sperry, B. W., Ikram, A., Hachamovitch, R., Valent, J., Vranian, M. N., Phelan, D., & Hanna,
M. (2016). Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting
With Symptomatic Heart Failure. Journal of the American College of Cardiology, 67(25),
–2948. https://doi.org/10.1016/J.JACC.2016.03.593
Misiurewicz-Gabi, A. "Rare diseases in focus." Kurier Medyczny 2019.4: 6-8.
Coelho, T., Merlini, G., Bulawa, C.E. et al. Mechanism of Action and Clinical Application of
Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther 5, 1–25 (2016).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Hanna Senat, Patrycja Grabowska, Aleksandra Senat, Patrycja Bolla, Aleksandra Madej, Iwona Matus, Natalia Janicka, Zuzanna Marczynska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 213
Number of citations: 0